glp 1 heart failure reduced ejection fraction Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit

Early trials of GLP-1 based drugs have shown promising results in patients with heart failure with preserved ejection fraction., A new study in JAMA uses real-world evidence that complements these

28.21

★★★★☆4.8 (126)

GLP-1 Receptor Agonists in Heart Failure Management

24.72

★★★★★4.9 (98)

26-A-13687-ACC SAFETY AND EFFICACY OF GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED AND MILDLY REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

29.46

★★★★★5.0 (157)

GLP-1 RA and HFpEF. GLP-1 RA improves left ventricular diastolic function.

20.54

★★★★★4.7 (84)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

23.69

★★★★★4.9 (203)

Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure

29.44

★★★★★5.0 (176)

Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials

27.24

★★★★★4.8 (132)